TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03413358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sheng Bai oral liquid
Description: Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses
Study: NCT01089595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 400 mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib with Imatinib
Description: Nilotinib 400 mg po BID Imatinib 400 mg po daily
Study: NCT03413358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based two medicine (carboplatin / cisplatin) .
Description: Using Platinum-based two medicine (carboplatin / cisplatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based two medicine (carboplatin / cisplatin) .
Description: Using Platinum-based two medicine (carboplatin / cisplatin)
Study: NCT01987544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometer Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergometer Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation
Study: NCT02874898

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Imaginal Exposure
Description: Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Imaginal Exposure
Description: Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
Study: NCT02807090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Stabilization Exercise
Description: There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circular dance
Description: There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
Study: NCT04581746

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire
Description: bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
Study: NCT04200924

Intervention type: OTHER
Intervention: Biodex Balance System
Description: For the computerized evaluation of postural control, Biodex Balance System will be used.

Intervention type: OTHER
Intervention: Biodex Balance System
Description: For the computerized evaluation of postural control, Biodex Balance System will be used.

Intervention type: OTHER
Intervention: Balance Error Scoring System (BESS)
Description: For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.

Intervention type: OTHER
Intervention: Balance Error Scoring System (BESS)
Description: For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
Study: NCT02745405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat Suit
Description: Participants wear a fat suit.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Participants wear same clothing as intervention, but in their own size.
Study: NCT03022630

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Palliative Care services
Description: Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual hepatic care
Description: Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
Study: NCT04649554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate treatment
Description: Ablation
Study: NCT02149160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRM-0334
Study: NCT01891461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
Study: NCT03207503

Intervention type: PROCEDURE
Intervention: fMRI
Description: Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.

Intervention type: PROCEDURE
Intervention: fMRI
Description: Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
Study: NCT02149160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRM-0334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00924651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: home based walking and progressive resistance training exercise
Study: NCT04345185

Intervention type: OTHER
Intervention: Infant egg consumption (i.e., age of introduction and frequency of intake)
Study: NCT03879109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy FOLFIRINOX, 6 cycles
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy FOLFIRINOX, 6 cycles
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)
Study: NCT01355406

Intervention type: DEVICE
Group type: OTHER
Intervention: FlexStent® Femoropopliteal Self Expanding Stent System
Description: Transcatheter over guidewire placement of an intravascular stent(s)
Study: NCT02132221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
Study: NCT03540823

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Description: Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Description: Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
Study: NCT03028493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original SAFE Intervention
Description: A CDC recommended, evidence-based falls prevention intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted SAFE Intervention
Description: An adapted version of the SAFE intervention meant to target older adults with low vision.
Study: NCT00230321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
Study: NCT01088308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High rate atrial and vetricular stimulation
Description: The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventricular Tachycardia induction
Description: A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
Study: NCT04063111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum assistant closure
Description: Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL DRESSING
Description: CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
Study: NCT03879109

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Description: Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
Study: NCT04680884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental for steroid
Description: 2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental for antifungals
Description: IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental for steroids and antifungals
Description: IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
Study: NCT03879109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)
Study: NCT04134871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group walk and one to one coaching
Description: Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
Study: NCT01595828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Study: NCT03022175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR741
Description: SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Study: NCT00972738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: loratadine
Description: Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
Study: NCT02322593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-118 plus Oxaliplatin
Study: NCT02220686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Offer and Report Protocol
Description: Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
Study: NCT00972738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: placebo tablet orally once daily at bedtime for 2 weeks
Study: NCT00934882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
Study: NCT03568903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive physical therapy
Description: Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
Study: NCT02951650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberonics VNS
Description: Vagus nerve stimulation
Study: NCT04680884

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
Study: NCT05086822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: Irinotecan liposome
Study: NCT01622101

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thermogenic properties of Zantrex-3®
Description: The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thermogenic properties of Zantrex-3®
Description: The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
Study: NCT03931837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet: Systolic blood pressure + 75 mmHg
Description: Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet: Systolic blood pressure + 100 mmHg
Description: Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet: Systolic blood pressure + 150 mmHg
Description: Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
Study: NCT02216409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4
Study: NCT02357992

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SABR)
Description: SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
Study: NCT01319955

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
Study: NCT03238469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
Study: NCT02219542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: transversus abdominis plane block
Description: transversus abdominis plane block with 20 mL saline
Study: NCT01319955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
Study: NCT01419990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 300 mg oral capsules, qd, 10 days
Study: NCT03729596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate
Study: NCT02322593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 plus Cisplatin
Study: NCT01419990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 450 mg oral capsules, qd, 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules, qd, 10 days
Study: NCT02571413

Intervention type: OTHER
Group type: OTHER
Intervention: score before teaching
Description: score the check-point of correct INCS usage before teaching
Study: NCT02219542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transversus abdominis plane block
Description: transversus abdominis plane block with 20 mL 0.25% ropivacaine
Study: NCT00835978

Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: axitinib 5mg BID (open-label) + axitinib dose titration (blinded)